Journal of Diagnostics Concepts & Practice >
Interpretation of the Clinical Practice Guidelines for Non-small Lung Cancer (version 4 and version 5) of 2022 National Comprehensive Cancer Nerwork(NCCN)
Received date: 2022-12-13
Online published: 2023-07-06
Lung cancer is the leading cause of cancer-related deaths worldwide, with approximately 1.8 million patients dying of lung cancer each year, accounting for 18.0% of all cancer deaths. Non-small cell lung cancer (NSCLC) is the main type of lung cancer and accounts for more than 85% of all lung cancer patients. In China, more than 700 000 new cases of lung cancer are diagnosed each year, and more than 600 000 patients die of lung cancer, accounting for 21.7% of all cancer deaths. In 2022, the National Comprehensive Cancer Network (NCCN) updated the guidelines for clinical diagnosis and treatment of lung cancer. Compared with the third edition of the guidelines, the fourth edition of the guidelines added the reference significance of ERBB2 (HER2) mutation in the diagnosis and treatment of （NSCLC）. The updated content was mainly focused on the detection of HER2 mutation as a standard biomarker and the treatment of patients with HER2 mutation. The detection of HER2 mutation is recommended for patients with metastatic NSCLC. Fam-trastuzumab deruxtecan and trastuzumab emtansine are recommended as second-line treatment options for patients with HER2 mutation. However, both are in clinical trials in China. The treatment strategies for NSCLC patients with HER2 mutations need to be considered comprehensively in light of the actual situation, and more data from domestic trials are needed. The fifth edition of the guidelines expanded the use of nivolumab, marking new progress in the study of immune checkpoint inhibitors.
CHEN Guoqun, CAI Jiaodi . Interpretation of the Clinical Practice Guidelines for Non-small Lung Cancer (version 4 and version 5) of 2022 National Comprehensive Cancer Nerwork(NCCN)[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(01) : 8 -13 . DOI: 10.16150/j.1671-2870.2023.01.002
| [1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
| [2] | CHENG M, JOLLY S, QUARSHIE W O, et al. Modern radiation further improves survival in non-small cell lung cancer: an analysis of 288,670 patients[J]. J Cancer, 2019, 10(1):168-177. |
| [3] | PARASCANDOLA M, XIAO L. Tobacco and the lung cancer epidemic in China[J]. Transl Lung Cancer Res, 2019, 8(Suppl 1):S21-S30. |
| [4] | CAO M, LI H, SUN D, et al. Cancer burden of major cancers in China: A need for sustainable actions[J]. Cancer Commun (Lond), 2020, 40(5):205-210. |
| [5] | CAO M, CHEN W. Epidemiology of lung cancer in China[J]. Thorac Cancer, 2019, 10(1):3-7. |
| [6] | OFFIN M, FELDMAN D, NI A, et al. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers[J]. Cancer, 2019, 125(24):4380-4387. |
| [7] | YANG C Y, YANG J C, YANG P C. Precision management of advanced non-small cell lung cancer[J]. Annu Rev Med, 2020, 71:117-136. |
| [8] | PILLAI R N, BEHERA M, BERRY L D, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium[J]. Cancer, 2017, 123(21):4099-4105. |
| [9] | WEI X W, GAO X, ZHANG X C, et al. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer[J]. Thorac Cancer, 2020, 11(6):1512-1521. |
| [10] | OU S H, KWAK E L, SIWAK-TAPP C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. J Thorac Oncol, 2011, 6(5): 942-946. |
| [11] | WOLF J, SETO T, HAN JY, et al. Capmatinib in MET exon 14-mutated or met-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10):944-957. |
| [12] | OWADA-OZAKI Y, MUTO S, TAKAGI H, et al. Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: brief report[J]. J Thorac Oncol, 2018, 13(8):1217-1221. |
| [13] | SCHROCK A B, LI S D, FRAMPTON G M, et al. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic Profi-ling[J]. J Thorac Oncol, 2017, 12(6):932-942. |
| [14] | MCGRANAHAN N, FURNESS A J, ROSENTHAL R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280):1463-1469. |
| [15] | LI B T, SMIT E F, GOTO Y, et al. Trastuzumab deruxtecan in her2-mutant non-small-cell lung cancer[J]. N Engl J Med, 2022, 386(3):241-251. |
| [16] | LI B T, SHEN R, BUONOCORE D, et al. Ado-Trastuzumab emtansine for patients with her2-mutant lung cancers: results from a phase Ⅱ basket trial[J]. J Clin Oncol, 2018, 36(24):2532-2537. |
| [17] | ZHOU C, RAMALINGAM S S, KIM T M, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomi-zed clinical trial[J]. JAMA Oncol, 2021, 7(12):e214761. |
| [18] | RIELY G J, NEAL J W, CAMIDGE D R, et al. Activity and safety of mobocertinib (tak-788) in previously treated non-small cell lung cancer with egfr exon 20 insertion mutations from a phase Ⅰ/Ⅱ trial[J]. Cancer Discov, 2021, 11(7):1688-1699. |
| [19] | YUAN B, ZHAO J, ZHOU C, et al. Co-occurring alterations of ERBB2 exon 20 insertion in non-small cell lung cancer (NSCLC) and the potential indicator of response to afatinib[J]. Front Oncol, 2020, 10:729. |
| [20] | CAPPUZZO F, BEMIS L, VARELLA-GARCIA M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer[J]. N Engl J Med, 2006, 354(24):2619-2621. |
| [21] | MAZIèRES J, PETERS S, LEPAGE B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives[J]. J Clin Oncol, 2013, 31(16):1997-2003. |
| [22] | MAZIERES J, DRILON A, LUSQUE A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8):1321-1328. |
| [23] | GUISIER F, DUBOS-ARVIS C, VI?AS F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4):628-636. |
| [24] | FAN Y, QIU J, YU R, et al. Clinical and molecular charac-teristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations[J]. Mol Oncol, 2020, 14(8):1731-1739. |
| [25] | FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivo-lumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21):1973-1985. |
| [26] | HANCOCK J G, ROSEN J E, ANTONICELLI A, et al. Impact of adjuvant treatment for microscopic residual di-sease after non-small cell lung cancer surgery[J]. Ann Thorac Surg, 2015, 99(2):406-413. |
| [27] | WU Y L, TSUBOI M, HE J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18):1711-1723. |
| [28] | FELIP E, ALTORKI N, ZHOU C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-ⅢA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308):1344-1357. |
/
| 〈 |
|
〉 |
